Rejuran Healer Injectionsin Seoul

Rejuran Healer adds no volume. It does not lift or fill a fold the way a hyaluronic acid filler does. The polynucleotide chains are thought to support the skin's own repair activity in the dermis, and the change people look for is in quality: thickness, fine lines, pore size and how evenly light reflects off the cheeks. That makes the injection a match for thin, tired-looking or post-acne skin, and a poor match for deep folds or sagging that needs structural support.

Because each syringe is spread through dozens of small punctures, anything that raises the chance of bruising or infection matters. The second list covers those cases.

Rejuran is a branded polynucleotide product. Polynucleotides are long chains of DNA fragments, and PDRN (polydeoxyribonucleotide) is a related, shorter-chain form from the same source. Laboratory and clinical work on PDRN describes an effect on wound healing through the adenosine A2A receptor (Squadrito, 2017), which is the background for using these molecules in skin. The two are close relatives, and studies on one do not transfer one-for-one to the other.

The injection itself is shallow. Small amounts are placed in the upper dermis at many points, and each deposit raises a small bump on the surface. Those bumps, known as embossing, are the product sitting where it was placed, and they flatten as it disperses over the next few days.

The clinic's price list separates four versions. Rejuran Healer comes in a 2 cc syringe and sits under the Skin Regeneration heading of the list, with a thinner 34G needle available as an add-on. Rejuran HB is a 1 cc syringe listed as the reduced-pain option and given with a 34G needle. Rejuran Eye, also 1 cc with a 34G needle, is listed for wrinkle improvement and is meant for the thin skin around the eyes. Rejuran S is a separate 1 cc line whose use is matched to the area being treated.

The research base is promising and still thin. A randomized, double-blind split-face trial found polynucleotide injections improved the eye area and were well tolerated, measured against a hyaluronic acid filler (Lee, 2020). A five-patient case series reported better texture and tone with no serious side effects, which is very early evidence (Park, 2015). An expert review in 2026 described polynucleotides as well tolerated while stating that larger controlled trials and tissue studies are still needed (Rho, 2026). In a pilot study on melasma, adding polynucleotides to microneedle RF did no better than the RF alone (Gulfan, 2022).

Placement is planned zone by zone, small, precise amounts where the skin is thinnest or roughest.

Rejuran is priced per syringe. Healer is sold as a 2 cc syringe, while HB, Eye and S are 1 cc each, so comparing them by cost alone mixes two volumes. A full-face Healer session and a targeted eye-area session are different purchases even when the totals look close.

The amounts on the cards leave out VAT. A 10% tax is added at payment, and each card prints the VAT-inclusive total beside the base figure. The 34G needle is an extra for Healer only; HB and Eye already come with it. Combining versions, for example Healer on the cheeks and Eye under the eyes, means adding the syringes together, and your written quote lists each one.

Polynucleotide injections are shallow, yet each one is still a needle puncture with product left behind:

• Raised bumps, redness and mild swelling at injection points for 1–3 days.
• Bruising that can take 1–2 weeks to clear, more likely with blood thinners.
• Infection at puncture sites, or a cold sore flare in people who carry the virus.
• Allergic or hypersensitivity reactions, including in people sensitive to fish-derived ingredients.
• Small lumps or uneven texture if product gathers in one spot.
• Stinging during injection despite numbing cream, felt most on thin skin near the eyes.
• A temporary change: the clinic reports results lasting about 1–3 months, and research on polynucleotides is still limited.

Message the clinic promptly if a bump becomes hot and painful, swelling grows after day 3, or a rash or breathing difficulty appears.